Forward Pharma A/S presently engages in very limited business activities. In the past, this biopharmaceutical firm concentrated its efforts on developing FP187, its distinctive formulation of dimethyl fumarate, which was aimed at addressing both inflammatory and neurological conditions. The company was founded in 2005 and its headquarters are located in Copenhagen, Denmark.